Clinical Trial, Number Of Patients

No definition available.

Name:	dcth_ClinicalTrialNumberOfPatients
Namespace Prefix:	dcth_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Clinical Trial, Number Of Sites

+ References

No definition available.

+ Details

Name:	dcth_ClinicalTrialNumberOfSites
Namespace Prefix:	dcth_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Orphan Drug Designations Granted by US Food and Drug Administration

+ References

No definition available.

+ Details

Name:	dcth_NumberOfOrphanDrugDesignationsGrantedByUSFoodAndDrugAdministration
Namespace Prefix:	dcth_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Organization consolidation basis of presentation business description and accounting policies line item.

+ References

No definition available.

+ Details

Name:	dcth_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesLineItems
Namespace Prefix:	dcth_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Product Reimbursement Period

+ References

No definition available.

+ Details

Name:	dcth_ProductReimbursementPeriod
Namespace Prefix:	dcth_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1

+ Details

Name:	us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

+ Details

Name:	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	srt_ProductOrServiceAxis=dcth_HEPZATOKITMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dcth_HEPZATOKITMelphalanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dcth_HEPZATOKITDoxorubicinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dcth_CHEMOSATMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

General (Details) $ in Thousands	1 Months Ended
General (Details) $ in Thousands	Jun. 30, 2025	Jun. 30, 2026 USD ($) designation	Dec. 31, 2025 USD ($)	Oct. 18, 2025 patient	Apr. 28, 2025 patient site	Dec. 31, 2024 patient site
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Cash cash equivalents and restricted cash \| $		$ 47,500
Short-term investments \| $		$ 48,381	$ 47,582
HEPZATO KIT
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		6
Clinical trial, number of patients \| patient					90	90
Clinical trial, number of sites (more than) \| site					15	20
HEPZATO KIT, Melphalan
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		5
HEPZATO KIT, Doxorubicin
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Number of orphan drug designations granted by FDA		1
CHEMOSAT
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Line Items]
Product reimbursement period	2 years
Clinical trial, number of patients \| patient				76